STOCK TITAN
  1. Home
  2. Sec-filings
  3. RXRX
  4. [Form 4] Recursion Pharmaceuticals, Inc. Insider Trading Activity

Recursion Pharmaceuticals Reinforces Board Compensation with Stock Options and RSUs

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Recursion Pharmaceuticals (RXRX) director Blake Borgeson received new equity compensation grants on June 18, 2025. The insider was awarded:

  • 22,016 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
  • 44,031 stock options with an exercise price of $5.11, exercisable under the same vesting schedule as the RSUs

Following these transactions, Borgeson directly owns 7,089,863 shares of Class A Common Stock plus the newly granted options. The equity grants were made automatically pursuant to the company's Outside Director Compensation Policy. All awards are subject to continued service requirements. The filing was submitted by Jonathan Golightly as attorney-in-fact on June 23, 2025.

Positive

  • None.

Negative

  • None.
Insider Borgeson Blake
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 44,031 $0.00 $0.00
Grant/Award Class A Common Stock 22,016 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 44,031 shares (Direct); Class A Common Stock — 7,089,863 shares (Direct)
Footnotes (2)
  1. F1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
  2. F2. The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider trading activity occurred at RXRX on June 18, 2025?
Director Blake Borgeson received two equity grants: 22,016 restricted stock units (RSUs) and stock options to purchase 44,031 shares of Class A Common Stock at an exercise price of $5.11 per share.

What is the vesting schedule for RXRX Director Blake Borgeson's June 2025 stock grants?
Both the RSUs and stock options will vest on the earlier of June 18, 2026 or the day prior to RXRX's 2026 Annual Meeting of Stockholders, subject to Borgeson's continued service to the company.

How many shares of RXRX does Director Blake Borgeson own after the June 2025 transaction?
Following the transaction, Blake Borgeson directly owns 7,089,863 shares of RXRX Class A Common Stock, plus 44,031 unvested stock options.

What is the exercise price and expiration date of RXRX stock options granted to Borgeson in June 2025?
The stock options have an exercise price of $5.11 per share and expire on June 18, 2035, ten years from the grant date.

Was RXRX Director Borgeson's June 2025 stock grant part of a planned transaction?
Yes, the grants were automatically awarded pursuant to RXRX's Outside Director Compensation Policy, rather than being discretionary or market transactions.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Borgeson Blake
(Last) (First) (Middle)
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
(Street)
SALT LAKE CITY UT 84101
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/18/2025 A(1) 22,016 A $0 7,089,863 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $5.11 06/18/2025 A 44,031 (2) 06/18/2035 Class A Common Stock 44,031 $0 44,031 D
Explanation of Responses:
1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
2. The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
Remarks:
/s/Jonathan Golightly, attorney-in-fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR